WALTHAM, Mass., July 13, 2026
Q32 Bio has announced positive 36-week topline results from Part B of the Phase 2a SIGNAL-AA clinical trial evaluating bempikibart, its investigational anti-IL-7Rα antibody, in patients with severe and very severe alopecia areata (AA). The clinical-stage biotechnology company reported that the study achieved clinically meaningful efficacy on its primary endpoint while maintaining a favorable safety profile, supporting plans to advance the therapy into a registration-directed clinical development program in the first half of 2027. The findings reinforce the therapeutic potential of bempikibart as a differentiated immune-modulating treatment designed to restore adaptive immune balance by blocking IL-7 and TSLP signaling, offering a promising alternative for patients who require effective long-term therapies beyond currently available JAK inhibitors. The latest results strengthen Q32 Bio’s position in the autoimmune disease landscape and represent another important milestone in the development of innovative therapies targeting immune-mediated disorders.
Strong Clinical Efficacy Demonstrated in SIGNAL-AA Trial
The open-label Phase 2a SIGNAL-AA Part B study enrolled 33 patients with severe or very severe alopecia areata, including individuals previously treated with oral JAK inhibitors. The primary analysis demonstrated a 35.3% mean reduction in Severity of Alopecia Tool (SALT) score from baseline in the modified intent-to-treat population after 36 weeks of treatment. Additionally, 40% of patients achieved a SALT-20 response, while 44% reached both SALT30 and SALT50 response levels, reflecting substantial improvements in scalp hair regrowth. Importantly, researchers also observed early signs of durability, with several patients maintaining or further improving hair growth during the off-treatment follow-up period, including one participant achieving complete scalp hair regrowth (SALT = 0). These encouraging outcomes further validate the biological mechanism of bempikibart and support its potential as a first-line treatment option for patients with alopecia areata.
Favorable Safety Profile Supports Continued Development
Beyond its encouraging efficacy results, bempikibart demonstrated a generally well-tolerated safety profile, remaining consistent with findings from earlier clinical studies. Investigators reported no new safety signals, no treatment-related serious adverse events, and no Grade 3 or higher adverse events throughout the trial. The most commonly reported adverse event was mild injection-site reactions, which resolved without intervention. Pharmacokinetic, pharmacodynamic, and anti-drug antibody analyses also produced favorable findings, confirming effective drug exposure and minimal immunogenicity. These safety outcomes are particularly important given the long-term treatment needs of patients with autoimmune diseases and may provide a meaningful advantage over therapies associated with broader immune suppression or increased safety concerns.
Advertisement
Registration-Directed Development Planned for 2027
Q32 Bio believes the latest SIGNAL-AA results further establish bempikibart as a differentiated therapeutic candidate capable of delivering durable clinical benefit while addressing significant unmet medical needs in alopecia areata. The company intends to launch a registration-directed clinical program during the first half of 2027, while ongoing follow-up through Week 52 and the open-label extension study continue to evaluate long-term durability and maintenance dosing strategies. Researchers emphasized that targeting the IL-7Rα pathway offers a novel mechanism for restoring immune balance rather than broadly suppressing immune activity, potentially creating opportunities beyond alopecia areata across a wider range of autoimmune and inflammatory diseases. As development progresses, the positive Phase 2a findings position Q32 Bio among the emerging innovators advancing next-generation immunology therapies designed to provide safer, more durable, and clinically meaningful treatment options for patients living with chronic autoimmune disorders.
Source: Q32 Bio press release
